Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q8N5M1

UPID:
ATPF2_HUMAN

ALTERNATIVE NAMES:
ATP12 homolog

ALTERNATIVE UPACC:
Q8N5M1; A6NDE5; A8K2J2; Q6XYC7

BACKGROUND:
The ATP synthase mitochondrial F1 complex assembly factor 2, alternatively named ATP12 homolog, is essential for the proper assembly of the mitochondrial ATP synthase's F1 component. This process is critical for ATP production, the energy currency of the cell, highlighting the protein's importance in energy metabolism and mitochondrial function.

THERAPEUTIC SIGNIFICANCE:
Associated with Mitochondrial complex V deficiency, nuclear type 1, the protein's malfunction leads to diverse symptoms including psychomotor retardation and hypotonia. Insights into ATP synthase mitochondrial F1 complex assembly factor 2's function offer promising avenues for developing treatments for this complex mitochondrial disease.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.